jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Part of Placenta Biopsy

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histopathology of placenta.

₹370₹529

30% OFF

Placenta Biopsy - Comprehensive Medical Test Information Guide

  • Section 1: Why is it done?
    • Test Purpose: A placenta biopsy involves obtaining a tissue sample from the placenta during pregnancy to examine its structure, function, and cellular composition for abnormalities or pathological changes.
    • Primary Indications: Diagnosis of intrauterine growth restriction (IUGR), evaluation of recurrent pregnancy loss, assessment of placental abnormalities detected on ultrasound, investigation of maternal hypertension or preeclampsia, evaluation of suspected intrauterine infections, assessment of fetal abnormalities, determination of chromosomal abnormalities in the placenta, and evaluation of abnormal placental pathology.
    • Timing and Circumstances: Performed during pregnancy when placental pathology is suspected (typically second or third trimester), at delivery for examination of placentas with clinical concerns, or postpartum when complications warrant investigation. May be performed percutaneously under ultrasound guidance or collected at time of delivery.
    • Clinical Scenarios: Persistent oligohydramnios, abnormal umbilical artery Doppler studies, fetal anomalies, maternal infections (toxoplasmosis, cytomegalovirus, rubella), maternal diabetes with complications, placental insufficiency, and evaluation of stillbirth etiology.
  • Section 2: Normal Range
    • Normal Histological Findings: Well-developed chorionic villi with appropriate vascularity, normal trophoblastic layer without excessive fibrinoid necrosis, absence of significant inflammation, normal syncytiotrophoblast and cytotrophoblast layers, appropriate maternal-fetal interface development.
    • Normal Measurements: Chorionic villi size appropriate for gestational age, normal villous tree branching pattern, normal nucleated red blood cell count (absent or minimal in normal term pregnancy), normal trophoblastic layer thickness (12-25 micrometers), absence of excessive fibrin deposition.
    • Microbiological Normal: Negative cultures for bacteria, viruses, and fungi; negative PCR testing for TORCH infections (Toxoplasma gondii, Rubella, Cytomegalovirus, Herpes simplex); negative for other maternal infections.
    • Cytogenetic Normal: Normal karyotype 46,XX or 46,XY, normal chromosome number without trisomies, normal ploidy, absence of mosaicism or structural chromosomal abnormalities.
    • Interpretation of Results: Normal = no significant pathology identified; Abnormal = presence of inflammatory changes, infectious organisms, chromosomal abnormalities, or placental insufficiency; Borderline = subtle findings requiring clinical correlation and possible additional testing.
  • Section 3: Interpretation
    • Villitis (Placental Inflammation): Indicates chronic placental infection or immune response; may be associated with recurrent pregnancy loss, preterm delivery, or intrauterine fetal death; requires identification of causative pathogen through culture or PCR.
    • Chorioamnionitis: Evidence of acute inflammation in chorion and amnion; suggests intrauterine infection; associated with preterm labor, premature rupture of membranes, and fetal complications; may be subclinical or clinically apparent.
    • Placental Insufficiency: Histological findings include villous hypoplasia, reduced villous surface area, excessive syncytial knots, and abnormal maternal-fetal interface; associated with IUGR, maternal hypertension, preeclampsia, and maternal vascular disease.
    • TORCH Infections: Positive PCR or culture for Toxoplasma, Rubella, CMV, or HSV; indicates transplacental transmission risk; associated with fetal abnormalities, developmental delays, and congenital disease; requires urgent fetal and neonatal management.
    • Chromosomal Abnormalities: Trisomy 13, 18, or 21 in placental tissue; may indicate fetal aneuploidy or placental mosaicism; requires correlation with fetal karyotyping; associated with adverse pregnancy outcomes.
    • Placental Mosaicism: Confined placental mosaicism (CPM) where abnormal cells present only in placenta, not fetus; most commonly benign but may warrant fetal testing; clinical significance depends on type and proportion of abnormal cells.
    • Meconium Staining: Indicates fetal distress in utero; evidence of meconium aspiration risk; may correlate with neonatal complications; timing of passage provides information about duration of fetal compromise.
    • Findings Requiring Clinical Correlation: Maternal floor infarction, perivillous fibrin deposition, retroplacental hemorrhage, placental abruption, and abnormal umbilical cord insertion; clinical significance depends on extent, gestational age, and associated fetal/maternal symptoms.
  • Section 4: Associated Organs
    • Primary Organ System - Reproductive/Placental: Placenta, umbilical cord, fetal membranes (amnion and chorion), decidua, and trophoblastic tissue; these structures comprise the placental unit responsible for maternal-fetal gas exchange, nutrient transfer, and immune function.
    • Secondary Organ Systems Affected: Central nervous system (fetal brain development affected by infections/insufficiency), cardiovascular system (reflected in Doppler abnormalities), endocrine system (hormonal production disruption), and hematologic system (altered oxygen transport).
    • Conditions Associated with Abnormal Results: Intrauterine growth restriction, preeclampsia, gestational hypertension, placental abruption, placenta previa, recurrent pregnancy loss, preterm labor, congenital infections (TORCH, syphilis), gestational diabetes complications, and maternal thrombophilia.
    • Diseases Diagnosed or Monitored: Placental insufficiency syndromes, chronic villitis of unknown etiology (CVUE), acute chorioamnionitis, congenital infections, placental abnormalities (accreta, increta, percreta), maternal vascular underperfusion lesions, and recurrent implantation failure.
    • Potential Complications from Abnormal Results: Fetal compromise, preterm delivery, neonatal complications (respiratory distress, infection), neurodevelopmental impairment, fetal death in utero (FDIU), maternal complications (severe preeclampsia, eclampsia, placental abruption requiring emergency delivery).
    • Long-term Maternal Health Implications: Placental pathology may indicate underlying maternal vascular disease (hypertension, diabetes, thrombophilia); may predict future pregnancy complications and cardiovascular disease risk; requires ongoing medical surveillance.
    • Long-term Fetal/Neonatal Health Implications: Congenital infections may result in permanent sequelae including blindness, deafness, intellectual disability, and cardiac defects; placental insufficiency linked to increased risk of childhood hypertension, obesity, and metabolic disease; intrauterine growth restriction associated with developmental delays.
  • Section 5: Follow-up Tests
    • Microbiological Follow-up: Maternal serology for TORCH infections; fetal serology and PCR testing from amniotic fluid; neonatal blood and CSF culture; viral culture and PCR from placental and cord blood; maternal blood cultures for bacterial infections.
    • Genetic/Cytogenetic Follow-up: Fetal karyotyping (amniocentesis or chorionic villus sampling if during pregnancy); neonatal karyotyping; chromosomal microarray (CMA) for finer resolution; fluorescence in situ hybridization (FISH) for rapid aneuploidy detection; next-generation sequencing for detailed genetic analysis.
    • Imaging Follow-up: Repeat ultrasound for fetal biometry and Doppler assessment (umbilical artery, middle cerebral artery); fetal MRI for detailed anatomy; neonatal neuroimaging if congenital infection suspected; placental ultrasound assessment for abnormalities.
    • Obstetric Management Tests: Non-stress testing (NST) for fetal heart rate reactivity; biophysical profile (BPP) for fetal well-being assessment; maternal laboratory studies (complete blood count, liver function tests, coagulation studies if preeclampsia); thrombophilia screening if recurrent pregnancy loss.
    • Neonatal Screening and Assessment: Newborn metabolic screening; hearing screening; ophthalmologic evaluation if congenital infection; developmental assessment at 6-12 months; early intervention programs for at-risk infants.
    • Maternal Follow-up Testing: Blood pressure monitoring postpartum; proteinuria assessment (24-hour urine) if preeclampsia; glucose tolerance testing if gestational diabetes; thrombophilia testing if placental abruption or recurrent loss; cardiovascular risk stratification in future pregnancies.
    • Monitoring Frequency for Ongoing Conditions: IUGR: twice-weekly fetal surveillance; preeclampsia: twice weekly to daily assessment depending on severity; placental insufficiency: weekly ultrasound and NST; congenital infection: neonatal monitoring for first 2 weeks, then developmental follow-up at 3, 6, 12 months; recurrent pregnancy loss: preconception evaluation and early pregnancy assessment in subsequent pregnancies.
    • Complementary Testing: Placental immunohistochemistry for specific pathogen identification; electron microscopy for viral inclusions; flow cytometry for inflammatory cell characterization; molecular pathology for genetic mosaicism characterization.
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is not required for placenta biopsy. This is a tissue sampling procedure rather than a laboratory blood test.
    • Pre-procedure Preparation (if performed in-utero): No fasting necessary; may eat and drink normally before procedure; light meal 1-2 hours before is acceptable; maintain normal hydration.
    • General Pre-procedure Instructions: Informed consent documentation; fetal viability confirmation (ultrasound); blood type and antibody screening; baseline vital signs and fetal heart rate; discuss risks and benefits with physician; arrange for support person if available.
    • Medications - Avoid or Modify: Anticoagulants (warfarin, dabigatran, rivaroxaban) should be held 24-48 hours prior; antiplatelet agents (aspirin, NSAIDs) should be held 5-7 days prior; discuss with physician before discontinuing any medications; prophylactic antibiotics may be considered in specific cases.
    • Post-procedure Instructions: Pelvic rest for 48 hours after procedure; avoid strenuous activity for 1 week; monitor for vaginal bleeding, fluid leakage, cramping, or fever; report symptoms immediately to physician; may resume normal diet immediately; hydration encouraged.
    • Special Considerations for Pregnant Patients: Rh-negative patients should receive RhoGAM within 72 hours if placental biopsy performed during pregnancy; Rh status must be determined prior to procedure; timing of RhoGAM dosage depends on gestational age and volume of fetal blood exposure.
    • At-Delivery Biopsy (No Special Preparation Needed): When biopsy is obtained after delivery, no advance preparation is necessary; specimen should be collected immediately after placental expulsion; must be placed in appropriate fixative (usually 10% neutral buffered formalin) or submitted fresh depending on testing requirements; proper labeling and chain of custody essential.
    • Additional Patient Instructions: Wear comfortable, loose-fitting clothing; arrange transportation if sedation used; contact emergency department if severe complications develop (uncontrolled bleeding, severe pain, signs of infection); follow-up appointment should be scheduled within 1-2 weeks to discuss results and implications.

How our test process works!

customers
customers